VivopureX™ Recombinant Antibodies for In Vivo Research
Product News Jan 07, 2020
Absolute Antibody Ltd., a provider of recombinant antibody products and services, has announced the launch of its VivopureX™ recombinant mouse antibodies for in vivo research in mouse models. The collection consists of popular antibody clones, many originally obtained from rats or hamsters, which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions with the aim of improving research results. The antibodies are all available in discounted bulk sizes ranging from 1 mg to 100 mg.
VivopureX™ antibodies are species-matched chimeric antibodies, consisting of a clone’s original antigen-binding variable domain with a mouse constant domain, which means they do not induce neutralizing antibodies in mouse models. As a result, the engineered recombinant antibodies are designed to offer many advantages compared to the original monoclonal antibodies, including increased long-term efficacy, stronger potency and a more consistent response across cohorts. In addition, VivopureX™ antibodies feature engineered effector functions, with Fc receptor binding tailored to best suit popular applications such as depletion, agonism or blocking.
All antibodies are produced recombinantly for batch-to-batch reproducibility and aim to offer high purity and low endotoxin levels, which is suitable for in vivo applications. The antibodies are targeted against key immune system proteins, including clinically relevant checkpoint proteins such as PD-1, CTLA-4 and OX40.